X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The purpose of the study was to examine the effects of EHP-101 on cardiac and other organ fibrosis induced by angiotensin II, which is implicated in the progression of myocardial fibrosis.
Lead Product(s): EHP-101
Therapeutic Area: Immunology Product Name: EHP-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 02, 2021
Details:
EHP-101, a novel product candidate with a unique multi-modal mechanism of action, has demonstrated disease-modifying potential in validated preclinical models of multiple sclerosis.
Lead Product(s): EHP-101
Therapeutic Area: Neurology Product Name: EHP-101
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2021
Details:
EHP is currently initiating a Phase 2 clinical study for systemic sclerosis in Australia, New Zealand and the United States with EHP-101.
Lead Product(s): EHP-101
Therapeutic Area: Dermatology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2020
Details:
This EMA Orphan Designation to EHP-102 provides Emerald Health additional global advantages by recognizing the unmet need with Huntington’s Disease.
Lead Product(s): EHP-102
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 29, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
